Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rituximab-PECC Plus RIT Produces Long-Term Responses in DLBCL

Key clinical point: Rituximab-PECC (prednisolone, etoposide, chlorambucil, lomustine) induction plus 90Y-ibritumomab tiuxetan consolidation showed acceptable safety and positive clinical outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have failed or are ineligible for autologous stem cell transplantation (ASCT).

Major finding: The 1-year failure-free survival from the start of 90Y-ibritumomab tiuxetan was 52% and 2-year failure-free survival post-90Y-ibritumomab tiuxetan was 38%. The median failure-free survival after 90Y-ibritumomab tiuxetan consolidation was 15.1 months.

Study details: A phase 2 study of 62 patients with relapsed/refractory DLBCL who have failed or are ineligible for ASCT.

Disclosures: The study was funded by the Dutch Cancer Society. Spectrum and Bayer Schering Pharma AG provided the 90Y-ibritumomab tiuxetan for the study. The authors reported financial affiliations with Novartis and Roche.

Citation:

Lugtenburg PJ et al. Br J Haematol. 2019 Jul 10. doi: 10.1111/bjh.16087